Emergent BioSolutions (EBS) Change in Accured Expenses (2010 - 2026)

Emergent BioSolutions' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$20.2 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 37.27% year-over-year to -$20.2 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 108.57% increase from a year earlier, with the FY2025 full-year figure at -$10.2 million, down 182.93% from the prior year.
• Change in Accured Expenses eased to -$20.2 million in Q1 2026 per EBS's latest filing, from $16.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $22.2 million in Q4 2024 and bottomed at -$51.0 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is -$8.1 million (2024), against an average of -$8.3 million.
• Across the five-year window, Change in Accured Expenses soared 187.06% in 2024 and plunged 3027.27% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at -$18.3 million in 2022, then sank by 39.34% to -$25.5 million in 2023, then surged by 187.06% to $22.2 million in 2024, then declined by 24.32% to $16.8 million in 2025, then tumbled by 220.24% to -$20.2 million in 2026.
• Per Business Quant, the three latest EBS Change in Accured Expenses figures stand at -$20.2 million (Q1 2026), $16.8 million (Q4 2025), and $1.3 million (Q3 2025).